MARKET

VRTX

VRTX

Vertex Pharmaceuticals Inc
NASDAQ
435.17
+5.35
+1.24%
After Hours: 438.14 +2.97 +0.68% 19:33 05/11 EDT
OPEN
429.50
PREV CLOSE
429.82
HIGH
442.16
LOW
428.50
VOLUME
1.26M
TURNOVER
--
52 WEEK HIGH
507.92
52 WEEK LOW
362.50
MARKET CAP
110.45B
P/E (TTM)
25.80
1D
5D
1M
3M
1Y
5Y
1D
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
NASDAQ · 3h ago
Vertex executives join fireside chats at RBC Global Healthcare, Bernstein Strategic Decisions conferences
PUBT · 4h ago
Weekly Report: what happened at VRTX last week (0504-0508)?
Weekly Report · 14h ago
5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call
Barchart · 19h ago
A Look At Vertex Pharmaceuticals (VRTX) Valuation After CASGEVY Reimbursement Progress And Reaffirmed Guidance
Simply Wall St · 20h ago
Vertex’s German CASGEVY Deal And The Push Beyond Cystic Fibrosis
Simply Wall St · 2d ago
Most healthcare companies report higher Y/Y EPS in strong earnings week
Seeking Alpha · 2d ago
Vertex Pharmaceuticals Q2 2026 Earnings Preview
Seeking Alpha · 3d ago
More
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Webull offers Vertex Pharmaceuticals Inc stock information, including NASDAQ: VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.